Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (avaa uuden ikkunan)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Lähde‎: Cancer 2013;119(21):3784-7.

Arkistoitu‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (avaa uuden ikkunan)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (avaa uuden ikkunan)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Lähde‎: Lancet 1989;334(8655):122-4.

Arkistoitu‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (avaa uuden ikkunan)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (avaa uuden ikkunan)

Ben-Bassat I, Douer D, Ramot B.

Lähde‎: Eur J Haematol 1990;45(2):86-9.

Arkistoitu‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (avaa uuden ikkunan)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (avaa uuden ikkunan)

Dean A, Tuffin P.

Lähde‎: J Pain Symptom Manage 1997;13(1):20-4.

Arkistoitu‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (avaa uuden ikkunan)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (avaa uuden ikkunan)

Ford PA, Grant SJ, Mick R, Keck G.

Lähde‎: J Clin Oncol 2015;33(15):1674-9.

Arkistoitu‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (avaa uuden ikkunan)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (avaa uuden ikkunan)

Garewal HS, Durie BG.

Lähde‎: Scand J Haematol 1985;35(5):497-500.

Arkistoitu‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (avaa uuden ikkunan)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (avaa uuden ikkunan)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Lähde‎: Cancer 2006;107(1):136-40.

Arkistoitu‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (avaa uuden ikkunan)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (avaa uuden ikkunan)

Marshall A, Li A, Drucker A, Dzik W.

Lähde‎: Hematol Oncol 2016;34(3):147-53.

Arkistoitu‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (avaa uuden ikkunan)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (avaa uuden ikkunan)

Prokopchuk-Gauk O, Brose K.

Lähde‎: Cureus 2015;7(12):e428.

Arkistoitu‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (avaa uuden ikkunan)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (avaa uuden ikkunan)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Lähde‎: Leuk Lymphoma 1995;19(1-2):141-4.

Arkistoitu‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (avaa uuden ikkunan)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (avaa uuden ikkunan)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Lähde‎: Hematol Oncol 2008;26(4):241-6.

Arkistoitu‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (avaa uuden ikkunan)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (avaa uuden ikkunan)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Lähde‎: Am J Hematol 2006;81(9):720.

Arkistoitu‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (avaa uuden ikkunan)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (avaa uuden ikkunan)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Lähde‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Arkistoitu‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (avaa uuden ikkunan)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (avaa uuden ikkunan)

Erduran E, Bahadir A, Mutlu M.

Lähde‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Arkistoitu‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (avaa uuden ikkunan)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (avaa uuden ikkunan)

Franchini M, Veneri D, Lippi G.

Lähde‎: Bone Marrow Transplant 2007;39(12):729-35.

Arkistoitu‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (avaa uuden ikkunan)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (avaa uuden ikkunan)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Lähde‎: Am J Hematol 2002;69(3):219-22.

Arkistoitu‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (avaa uuden ikkunan)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (avaa uuden ikkunan)

Hsieh A, Cheong I.

Lähde‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Arkistoitu‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (avaa uuden ikkunan)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (avaa uuden ikkunan)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Lähde‎: Haemostasis 1996;26 Suppl 1:159-64.

Arkistoitu‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (avaa uuden ikkunan)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (avaa uuden ikkunan)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Lähde‎: Med Oncol 2010;27(1):16-9.

Arkistoitu‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (avaa uuden ikkunan)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (avaa uuden ikkunan)

Vidarsson B, Önundarson PT.

Lähde‎: Thromb Haemost 2000;83(4):634-5.

Arkistoitu‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (avaa uuden ikkunan)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (avaa uuden ikkunan)

Zver S, Andoljšek D, Černelč P.

Lähde‎: Eur J Haematol 2004;72(6):455-6.

Arkistoitu‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (avaa uuden ikkunan)

Management of bleeding complications of hematologic malignancies. (avaa uuden ikkunan)

Green D.

Lähde‎: Semin Thromb Hemost 2007;33(4):427-34.

Arkistoitu‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (avaa uuden ikkunan)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (avaa uuden ikkunan)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Lähde‎: Int J Lab Hematol 2013;35(4):457-9.

Arkistoitu‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (avaa uuden ikkunan)

Management of bleeding in patients with advanced cancer. (avaa uuden ikkunan)

Pereira J, Phan T.

Lähde‎: Oncologist 2004;9(5):561-70.

Arkistoitu‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (avaa uuden ikkunan)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (avaa uuden ikkunan)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Lähde‎: Haematologica 1997;82(5):584-7.

Arkistoitu‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (avaa uuden ikkunan)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (avaa uuden ikkunan)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Lähde‎: Bull Cancer 2006;93(2):E7-12.

Arkistoitu‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (avaa uuden ikkunan)